

Supplementary appendix

<i>Methods 1. Study Inclusion/Exclusion criteria</i>	2
Inclusion Criteria	2
Exclusion Criteria:	2
<i>Table S1-1. Summary of solicited systemic adverse events after each dosing</i>	4
<i>Table S1-2. Summary of solicited local adverse events after each dosing</i>	7
<i>Table S2. Summary of unsolicited and other adverse events</i>	9
<i>Table S3. Geometric Mean Titers and Geometric Mean Titer Ratio of neutralizing antibodies (in IU/mL)</i>	10

Methods 1. Study Inclusion/Exclusion criteria

Inclusion Criteria

Participants must have met all of the following inclusion criteria to be eligible for participation in this study:

1. Male or female participant aged 18 years and above at randomization.
2. Healthy adults or adults with pre-existing medical conditions who are in stable condition (obesity, endocrinological pathologies: diabetes, hyperthyroidism, hypothyroidism, etc., pneumopathies: asthma, emphysema, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), heart diseases: arterial hypertension (HTN), arrhythmias, heart failure (HF), etc., liver diseases, renal, neurologic: angiographic cerebral vasospasm (ACV), psychiatric). A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
3. Female participants:
 - a. A female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
 - b. If the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Highly effective methods of contraception include:
 - i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system
 - ii. Established use of hormonal methods (injectable, pill, patch, or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
 - iii. Azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history).
 - c. Have a negative pregnancy test
4. Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
5. Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

Exclusion Criteria:

Participants meeting one or more of the following criteria could not be enrolled in this clinical study:

1. Pregnant or breast feeding or have plan to become pregnant within 30 days after the last administration of study intervention.
2. Employees at the investigator's site, of the Sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study.

Prior/Concomitant Therapy

3. Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
4. Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
5. Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
6. Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
7. Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)- α inhibitors, e.g., infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
8. Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
9. Has received any other investigational or approved COVID-19 vaccine.

Medical Conditions

10. Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
11. A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
12. Bleeding disorder considered a contraindication to IM injection or phlebotomy.
13. Known SARS-CoV-2 infection in the 3 months prior to the first dose of study intervention.
14. A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.
15. Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
16. A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901 or AZD1222.
17. Body (oral, rectal, or ear) temperature $\geq 38.0^{\circ}\text{C}$ or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Table S1-1. Summary of solicited systemic adverse events after each dosing

Time point, Severity	n (%)		
	MVC-COV1901 N=520	AZD-1222 N=510	Total N=1030
Any Solicited Systemic AEs			
After Any Dose, All severity	225 (49.0%)	297 (58.2%)	552 (53.6%)
After First Dose, All severity	216 (41.5%)	264 (51.8%)	480 (46.6%)
After Second Dose, All severity	116 (24.9%)	106 (23.1%)	222 (24.0%)
Myalgia			
After Any Dose, All severity	117 (22.5%)	167 (32.7%)	284 (27.6%)
Grade 1	110 (21.2%)	152 (29.8%)	262 (25.4%)
Grade 2	21 (4.0%)	40 (7.8%)	61 (5.9%)
Grade 3	6 (1.2%)	4 (0.8%)	10 (1.0%)
After First Dose, All severity	86 (16.5%)	150 (29.4%)	236 (22.9%)
Grade 1	79 (15.2%)	132 (25.9%)	211 (20.5%)
Grade 2	13 (2.5%)	37 (7.3%)	50 (4.9%)
Grade 3	1 (0.2%)	4 (0.8%)	5 (0.5%)
After Second Dose, All severity	52 (11.2%)	39 (8.5%)	91 (9.8%)
Grade 1	47 (10.1%)	34 (7.4%)	81 (8.8%)
Grade 2	10 (2.1%)	7 (1.5%)	17 (1.8%)
Grade 3	5 (1.1%)	0 (0.0%)	5 (0.5%)
Malaise/Fatigue			
After Any Dose, All severity	107 (20.6%)	141 (27.6%)	248 (24.1%)
Grade 1	101 (19.4%)	126 (24.7%)	227 (22.0%)
Grade 2	3 (0.6%)	5 (1.0%)	8 (0.8%)
Grade 3	3 (0.6%)	5 (1.0%)	8 (0.8%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After First Dose, All severity	75 (14.4%)	115 (22.5%)	190 (18.4%)
Grade 1	71 (13.7%)	99 (19.4%)	170 (16.5%)
Grade 2	15 (2.9%)	28 (5.5%)	43 (4.2%)
Grade 3	2 (0.4%)	2 (0.4%)	4 (0.4%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After Second Dose, All severity	53 (11.4%)	45 (9.8%)	98 (10.6%)
Grade 1	50 (10.7%)	41 (8.9%)	91 (9.8%)
Grade 2	12 (2.6%)	7 (1.5%)	19 (2.1%)
Grade 3	1 (0.2%)	3 (0.7%)	4 (0.4%)
Headache			
After Any Dose, All severity	146 (28.1%)	192 (37.6%)	338 (32.8%)
Grade 1	136 (26.2%)	166 (32.5%)	302 (29.3%)

Time point, Severity	n (%)		
	MVC-COV1901 N=520	AZD-1222 N=510	Total N=1030
Grade 2	31 (6.0%)	45 (8.8%)	76 (7.4%)
Grade 3	5 (1.0%)	10 (2.0%)	15 (1.5%)
After First Dose, All severity	116 (22.3%)	165 (32.4%)	281 (27.3%)
Grade 1	106 (20.4%)	142 (27.8%)	248 (24.1%)
Grade 2	21 (4.0%)	36 (7.1%)	57 (5.5%)
Grade 3	2 (0.4%)	10 (2.0%)	12 (1.2%)
After Second Dose, All severity	60 (12.9%)	59 (12.9%)	119 (12.9%)
Grade 1	53 (11.4%)	53 (11.5%)	106 (11.5%)
Grade 2	14 (3.0%)	9 (2.0%)	23 (2.5%)
Grade 3	3 (0.6%)	1 (0.2%)	4 (0.4%)
Fever			
After Any Dose, All severity	54 (10.4%)	97 (19.0%)	151 (14.7%)
Grade 1	33 (6.3%)	73 (14.3%)	106 (10.3%)
Grade 3	21 (4.0%)	31 (6.1%)	52 (5.0%)
After First Dose, All severity	35 (6.7%)	86 (16.9%)	121 (11.7%)
Grade 1	24 (4.6%)	65 (12.7%)	89 (8.6%)
Grade 3	11 (2.1%)	23 (4.5%)	34 (3.3%)
After Second Dose, All severity	22 (4.7%)	20 (4.4%)	42 (4.5%)
Grade 1	12 (2.6%)	14 (3.1%)	26 (2.8%)
Grade 3	10 (2.1%)	8 (1.7%)	18 (1.9%)
Chills			
After Any Dose, All severity	40 (7.7%)	77 (15.1%)	117 (11.4%)
Grade 1	38 (7.3%)	67 (13.1%)	105 (10.2%)
Grade 2	8 (1.5%)	12 (2.4%)	20 (1.9%)
Grade 3	2 (0.4%)	3 (0.6%)	5 (0.5%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After First Dose, All severity	25 (4.8%)	68 (13.3%)	93 (9.0%)
Grade 1	24 (4.6%)	59 (11.6%)	83 (8.1%)
Grade 2	6 (1.2%)	10 (2.0%)	16 (1.6%)
Grade 3	0 (0.0%)	3 (0.6%)	3 (0.3%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After Second Dose, All severity	21 (4.5%)	15 (3.3%)	36 (3.9%)
Grade 1	19 (4.1%)	14 (3.1%)	33 (3.6%)
Grade 2	3 (0.6%)	2 (0.4%)	5 (0.5%)
Grade 3	2 (0.4%)	0 (0.0%)	2 (0.2%)
Joint Pain			
After Any Dose, All severity	59 (11.3%)	93 (18.2%)	152 (14.8%)
Grade 1	53 (10.2%)	87 (17.1%)	140 (13.6%)
Grade 2	12 (2.3%)	20 (3.9%)	32 (3.1%)

Time point, Severity	n (%)		
	MVC-COV1901 N=520	AZD-1222 N=510	Total N=1030
Grade 3	2 (0.4%)	3 (0.6%)	5 (0.5%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After First Dose, All severity	41 (7.9%)	78 (15.3%)	119 (11.6%)
Grade 1	40 (7.7%)	71 (13.9%)	111 (10.8%)
Grade 2	3 (0.6%)	16 (3.1%)	19 (1.8%)
Grade 3	1 (0.2%)	3 (0.6%)	4 (0.4%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After Second Dose, All severity	23 (4.9%)	24 (5.2%)	47 (5.1%)
Grade 1	15 (3.2%)	22 (4.8%)	37 (4.0%)
Grade 2	10 (2.1%)	5 (1.1%)	15 (1.6%)
Grade 3	1 (0.2%)	0 (0.0%)	1 (0.1%)
Diarrhea			
After Any Dose, All severity	39 (7.5%)	44 (8.6%)	83 (8.1%)
After First Dose, All severity	26 (5.0%)	29 (5.7%)	55 (5.3%)
After Second Dose, All severity	14 (3.0%)	16 (3.5%)	30 (3.2%)
Nausea			
After Any Dose, All severity	60 (11.5%)	51 (10.0%)	111 (10.8%)
After First Dose, All severity	44 (8.5%)	41 (8.0%)	85 (8.3%)
After Second Dose, All severity	19 (4.1%)	16 (3.5%)	35 (3.8%)

Table S1-2. Summary of solicited local adverse events after each dosing

Time point, Severity	n (%)		
	MVC-COV1901 N=520	AZD-1222 N=510	Total N=1030
Any Solicited Local AEs			
After Any Dose, All severity	209 (40.2%)	256 (50.2%)	465 (45.1%)
After First Dose, All severity	140 (26.9%)	202 (39.6%)	342 (33.2%)
After Second Dose, All severity	123 (26.4%)	116 (25.3%)	239 (25.8%)
Pain/Tenderness			
After Any Dose, All severity	173 (33.3%)	215 (42.2%)	388 (37.7%)
Grade 1	166 (31.9%)	205 (40.2%)	371 (36.0%)
Grade 2	22 (4.2%)	42 (8.2%)	64 (6.2%)
Grade 3	5 (1.0%)	7 (1.4%)	12 (1.2%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After First Dose, All severity	105 (20.2%)	169 (33.1%)	274 (26.6%)
Grade 1	96 (18.5%)	158 (31.0%)	254 (24.7%)
Grade 2	19 (3.7%)	33 (6.5%)	52 (5.0%)
Grade 3	0 (0.0%)	6 (1.2%)	6 (0.6%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After Second Dose, All severity	100 (21.5%)	92 (20.0%)	192 (20.8%)
Grade 1	95 (20.4%)	86 (18.7%)	181 (19.6%)
Grade 2	8 (1.7%)	10 (2.2%)	18 (1.9%)
Grade 3	5 (1.1%)	1 (0.2%)	6 (0.6%)
Injection site pruritus			
After Any Dose, All severity	73 (14.0%)	81 (15.9%)	154 (15.0%)
Grade 1	67 (12.9%)	78 (15.3%)	145 (14.1%)
Grade 2	9 (1.7%)	5 (1.0%)	14 (1.4%)
Grade 3	1 (0.2%)	1 (0.2%)	2 (0.2%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After First Dose, All severity	60 (11.5%)	71 (13.9%)	131 (12.7%)
Grade 1	54 (10.4%)	68 (13.3%)	122 (11.8%)
Grade 2	9 (1.7%)	4 (0.8%)	13 (1.3%)
Grade 3	1 (0.2%)	1 (0.2%)	2 (0.2%)
Grade 4	0 (0.0%)	1 (0.2%)	1 (0.1%)
After Second Dose, All severity	31 (6.7%)	19 (4.1%)	50 (5.4%)
Grade 1	31 (6.7%)	19 (4.1%)	50 (5.4%)
Grade 2	0 (0.0%)	1 (0.2%)	1 (0.1%)
Erythema/Redness			
After Any Dose, All severity	10 (1.9%)	22 (4.3%)	32 (3.1%)
Grade 1	8 (1.5%)	18 (3.5%)	26 (2.5%)
Grade 2	2 (0.4%)	5 (1.0%)	7 (0.7%)
After First Dose, All severity	4 (0.8%)	14 (2.7%)	18 (1.7%)
Grade 1	3 (0.6%)	13 (2.5%)	16 (1.6%)
Grade 2	1 (0.2%)	3 (0.4%)	3 (0.3%)
After Second Dose, All severity	6 (1.3%)	8 (1.7%)	14 (1.5%)

Time point, Severity	n (%)		
	MVC-COV1901 N=520	AZD-1222 N=510	Total N=1030
Grade 1	5 (1.1%)	5 (1.1%)	10 (1.1%)
Grade 2	1 (0.2%)	3 (0.7%)	4 (0.4%)
Induration/Swelling			
After Any Dose, All severity	10 (2.0%)	13 (2.5%)	23 (2.2%)
Grade 1	8 (1.5%)	11 (2.2%)	19 (1.8%)
Grade 2	2 (0.4%)	3 (0.6%)	5 (0.5%)
After First Dose, All severity	7 (1.4%)	9 (1.8%)	16 (1.6%)
Grade 1	6 (1.2%)	8 (1.6%)	14 (1.4%)
Grade 2	1 (0.2%)	1 (0.2%)	2 (0.2%)
After Second Dose, All severity	3 (0.6%)	5 (1.0%)	8 (0.8%)
Grade 1	2 (0.4%)	3 (0.6%)	5 (0.5%)
Grade 2	1 (0.2%)	2 (0.4%)	3 (0.3%)
Hematoma			
After Any Dose, All severity	42 (8.1%)	43 (8.4%)	85 (8.3%)
Grade 2	29 (5.6%)	32 (6.3%)	61 (5.9%)
Grade 3	13 (2.5%)	12 (2.4%)	25 (2.4%)
After First Dose, All severity	33 (6.3%)	32 (6.3%)	65 (6.3%)
Grade 2	24 (4.6%)	22 (4.3%)	46 (4.5%)
Grade 3	9 (1.7%)	11 (2.2%)	20 (1.9%)
After Second Dose, All severity	14 (3.0%)	12 (2.6%)	26 (2.8%)
Grade 2	10 (2.1%)	11 (2.4%)	21 (2.3%)
Grade 3	4 (0.9%)	1 (0.2%)	5 (0.5%)

Table S2. Summary of unsolicited and other adverse events

	MVC-COV1901 N=520		AZD-1222 N=510		Total N=1030	
	E	n (%)	E	n (%)	E	n (%)
Unsolicited AEs	11	8 (1.5)	9	8 (1.6)	20	16 (1.6)
Unsolicited AEs ≥ Grade 3	2	2 (0.4)	1	1 (0.2)	3	2 (0.3)
SAEs	2	2 (0.4)	1	1 (0.2)	3	3 (0.3)
Related SAEs	0	0	0	0	0	0
AEs ≥ Grade 3	73	50 (9.6)	95	69 (13.5)	168	119 (11.6)
AESI	1	1(0.2)	0	0	1	1(0.1)
VAED	0	0	0	0	0	0
AEs leading to study intervention discontinuation	2	2 (0.4)	1	1 (0.2)	3	3 (0.3)
AEs leading to study withdrawal	0	0	0	0	0	0
Death	0	0	0	0	0	0

Abbreviation: E=no. of events, AE=adverse event, SAE= serious adverse event, AESI=adverse events of special interest, VAED= vaccine-associated enhanced disease

Note: % = percentage of participants with N as the denominator; participants might be counted in more than one category; exact 95% CIs are presented.

Table S3. Geometric Mean Titers and Geometric Mean Titer Ratio of neutralizing antibodies (in IU/mL)

Parameter	Vaccine		GMT ratio ¹ (95% CI)	p-value ²
	AZD1222	MVC-COV1901		
Seropositive				
n	70	72		
<i>Baseline</i>				
GMT	76.4	73.2		
95%CI	59.9-97.4	57.6-93.1		
<i>Day 14 after 2nd shot</i>				
GMT	1143.4	1905.6	1.7	<0.001
95%CI	895.3-1460.2	1617.98-2244.3	(1.2-2.2)	
GMFR	14.97	26.02		
95% CI	10.6-21.1	19.5-34.7		
Seronegative				
n	39	44		
<i>Baseline</i>				
GMT	5.04	5.04		
95%CI	5.04-5.04	5.04-5.04		
<i>Day 14 after 2nd shot</i>				
GMT	90.4	434.6	4.8	<0.0001
95%CI	61.1-133.9	333.4-566.5	(3.01-7.7)	
GMFR	17.9	86.2		
95% CI	12.2-26.4	66.4-111.9		

Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer, GMFR= geometric mean fold rise

Note: [1] GMT ratio was computed as, $GMT_{MVC-COV1901}/GMT_{AZD1222}$

[2] p-value based on two-sample t test or Wilcoxon rank sum test